Financial Highlights: Torrent Pharma Share Price
Standalone Business: Torrent Pharma Value Research
Revenue from operations grew by around 15% YOY while degrew by 1.8% QOQ standing at 1695 crores
Expenses have been flat YOY and increased by around 7.5% and stood at 1117 crores
EBITDA stood at 628 crores growing 1.7% YOY & 20% QOQ
EBITDA Margin stood at 37% with a similar increment of 1% YOY & QOQ
PAT stood at 274 crores declining 8% YOY & 1.7% QOQ
PAT margin stood at 16% declining 1% YOY & 3% QOQ
Consolidated Business: Torrent Pharma Annual Report
Revenue from operations grew by around 10% YOY while grew by 3.8% QOQ standing at 2134 crores
Expenses have risen by 4% YOY & 7% QOQ and stood at 1457 crores
EBITDA stood at 717 crores growing 7.8% YOY & 15% QOQ
EBITDA Margin stood at 34% with a similar increment of 2% YOY & QOQ
PAT stood at 330 crores rising 2.8% YOY & 1.8% QOQ
PAT margin stood at 15% declining 1% YOY & 2% QOQ
Business Highlights: Torrent Pharma Technical Chart
Consolidated Revenue Geographical Breakup: Torrent Pharma Share Chart
Revenues – India including Contract Research & Manufacturing (53%), Brazil (8%), US (16%) and Germany (13%)
Indian Business stood at 1093 crores rising 18% YOY from 925 crores
United States business stood at 266 crores declining 29% YOY from 373 crores
Germany business stood at 260 crores rising 5% YOY from 246 crores
Brazil business stood at 153 crores rising 9% YOY from 140 crores
Other countries stood at 217 crores declining 7% YOY from 234 crores
Other Business Highlights: Torrent Pharma Stock Chart
Torrent grew 24% in Q1FY22 as per AIOCD vs. market growth of 37% in Domestic Formulations. It witnessed new product/price/volume growth of 14%/6%/4% YoY in the Domestic Formulation segment.
It launched four new products and a few extensions in Nutritional products in the Indian market in 1QFY22. The next wave of new launches will be when patents expire next year.
The Trade Generics segment will focus mainly on Acute and some sub-Chronic products. It may look to shift some products to the Trade segment, where consumer involvement and self-medication is higher.
The company exhibited a higher single-digit pricing impact across the portfolio on an annualized basis.
Margin affected by absence of export benefits, skewness towards acute portfolio in Q1FY22
Growth momentum in the Domestic Formulation (DF) business was offset by a muted showing in the US business and a higher tax rate.
It continues to work on alternate site filings to lower the impact of USFDA regulatory issues
Torrent launched trade generics division with focus on acute & sub chronic products
The company Initially start with 50-60 SKUs, and expects 3-4% revenue contribution to India business in near term
The company has assigned only 25 MRs and uses external distributors to sell its products
Four new products launched in Q1FY22, including baricitinib and extensions in nutritional products.
Torrent is currently conducting clinical trials for molnupiravir and looking to widen Covid portfolio
The management expects the double-digit growth to continue US sales
The company is facing high single digit price erosion in its base portfolio due to mature portfolio and new competition
The company is facing Lack of new launches impacting sales and management awaits USFDA response on Indrad and Dahej plants
The management plans to file 10-12 ANDAs per year with focus on complex generics and 505(b)(2) NDAs
As of Q1FY22 - 54 ANDAs pending approval, seven tentative approvals were received
The company repaid debt of 350 crores from cash flow from operations
We are the best website for ready-made portfolios. We are the Best Stock Advisory Service In India. Our stock-o-meter covers a very detailed analysis of companies. With best-managed portfolios, one can make sane investments. We have maintained a series of free financial eBooks which keeps you updated.